SPOT is a novel Clinician Decision Support Digital Health CE-marked medical device platform. Using AI, SPOT is able to harness information to enable the development of guidelines and predict prescriber performance to ensure safe and effective treatment of pain. SPOT supports prescribers switching patients addicted or misusing opioids to buprenorphine as part of a medication-assisted treatment regime to reduce the risk of opioid overdose death. SPOT is also used in palliative and end of life care settings to support opioid switch in cases of toxicity or unwanted side effects. In a real world, cross setting and multi-professional study in the NHS it is proven to significantly improve the confidence of opioid prescribing in users and adherence to best practice guidelines. SPOT is designed to reduce unwarranted variation and primary and secondary harms when prescribing opioids whilst supporting warranted variation of choice to align to individual situations, values and side effect profiles. SPOT is able to monitor drug usage and spend and suggest lower-cost opioids to users to reduce costs to healthcare organisations. SPOT is currently in use in the NHS.

SPOT is the only CE-Marked, clinically-validated equianalgesic opioid converter in clinical practice, assessed against the NHS Scotland Quality Assurance Framework for Medical Device Apps, based upon the Scottish Palliative Guidelines, proven to improve adherence to guidelines and con- fidence in prescribers which is ready for national-level adoption and is currently rolled out in an NHS Board. It is designed to support prescribers during shortages associated with the COVD19 pandemic and prescribers using unfamiliar opioids. It comes with the mandated software support, updates, indemnity and ongoing clinical appraisal to continue to fulfil this the National Assurance Framework. SPOT is part of NHS Scotland's Coronavirus Toolkit in response to COVID-19 https://www.gov.scot/publications/coronavirus-covid-19-palliative-care-toolkit/

Helping people with Medication & Counseling Treatment for Substance Use Disorder

PursueCare is a technology-enabled health services provider aiming to help solve the nation’s growing opioid epidemic through greater access to stigma-free treatment. The company has launched a first-of-its-kind telehealth opioid addiction treatment platform available to patients through an iOS/Android mobile app, tablet, or computer. Through a platform of services, patients can conveniently and quickly access Medication-Assisted Treatment like Suboxone from qualified physicians, addiction counseling, and mail-order medications from PursueCare's Joint Commission-accredited pharmacy. The platform provides on-demand, interventive, and transitional care to patients coming from hospital inpatient and emergency departments, primary care, and rural health clinic settings.

1. Clinical Validation - multi-site cross-professional study 2. CE-Mark + MDR. All medical device regulatory approvals 3. NHS Scotland Quality Assurance Framework for Medical Device Apps Approved https://rightdecision.scot.nhs.uk/spot-safer-prescribing-of-opiooids-tool/ 4. Ability to monitor prescriber performance and identify users and areas that would benefit from retraining and eduction 5. Monitor and manage opioid drug spend 6. Customise local formulary to offer lower-cost opioids first line to manage drug spend 7. Using AI, able to predict the likelihood of individual prescriber errors and the magnitude of the error. 8. Management reports allowing benchmarking between and within organisations and clinical areas

At PursueCare, our vision is to make comprehensive addiction treatment and mental health services accessible to everyone, everywhere. We’re working to remove the traditional obstacles to treatment that patients frequently encounter.